Philipp holds a PhD in Biochemistry from the University of Basel and has a long track record of working in translational immuno-oncology (IO) research, infectious diseases, and general drug discovery within the pharmaceutical industry. In 2015 he joined Boehringer Ingelheim´s IO department, where he led multidisciplinary research teams and delivered the IO research strategy for innovative platforms and biology areas. Contributing to Boehringer Ingelheim´s external innovation strategy he further identified, evaluated, initiated, and managed alliances with multiple external partners. Philipp joined the Boehringer Ingelheim Venture Fund (BIVF) as Investment Manager in 2020. With a focus on life sciences in Europe, he is responsible for identifying, evaluating, making, and managing equity investments to create options in new therapeutic approaches and businesses. In addition to Asgard Therapeutics, Philipp currently serves as a board member of ImCheck Therapeutics in Marseilles and represents the BIVF in the Selection Committee of the AMR-focused incubator INCATE.